PDCD1 and non-small cell lung carcinoma: Neutrophil-to-lymphocyte ratio (NLR), neutrophil-to-platelet Ratio (NPR) and lactate dehydrogenase (LDH) have been reported as predictors of prognosis and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors [40, 41].